PDF(Pubmed)
Abstract：
BACKGROUND: The blood urea nitrogen to serum albumin ratio (BAR) is an emerging prognostic parameter of interest. The utility of BAR as a prognostic factor has not been analyzed in lung cancer patients undergoing pulmonary lobectomy. We evaluated the ability of High BAR to predict worse outcomes after robotic-assisted pulmonary lobectomy (RAPL) for lung cancer.
METHODS: We retrospectively analyzed 400 patients who underwent RAPL from September 2010 to March 2022 by one surgeon. Patients were stratified by Low BAR (<6.25 mg/g) and High BAR (≥6.25 mg/g). Patients\' demographics, tumor characteristics, comorbidities, surgical complications, outcomes, and survival were collected and compared by High and Low BAR groups. The primary outcome of interest was 30-day mortality.
RESULTS: Receiver operator curves (ROC) confirmed that 6.25 was an optimal threshold for estimating mortality based on Low and High BAR. There were no differences in surgical complications or outcomes between the Low and High BAR groups. The ability of BAR to predict 30-day mortality was evaluated with the area under the curve (AUC) analysis, which showed that higher BAR could not predict mortality (AUC=0.655; 95% CI, 0.435-0.875; p=0.166). Similarly, survival analysis revealed no difference in five-year overall survival between the Low and High BAR groups (p=0.079).
CONCLUSIONS: High BAR did not predict worse outcomes after RAPL for lung cancer in our study. Further studies are needed to better determine the prognostic ability of BAR in lower-risk populations.
METHODS: We retrospectively analyzed 400 patients who underwent RAPL from September 2010 to March 2022 by one surgeon. Patients were stratified by Low BAR (<6.25 mg/g) and High BAR (≥6.25 mg/g). Patients\' demographics, tumor characteristics, comorbidities, surgical complications, outcomes, and survival were collected and compared by High and Low BAR groups. The primary outcome of interest was 30-day mortality.
RESULTS: Receiver operator curves (ROC) confirmed that 6.25 was an optimal threshold for estimating mortality based on Low and High BAR. There were no differences in surgical complications or outcomes between the Low and High BAR groups. The ability of BAR to predict 30-day mortality was evaluated with the area under the curve (AUC) analysis, which showed that higher BAR could not predict mortality (AUC=0.655; 95% CI, 0.435-0.875; p=0.166). Similarly, survival analysis revealed no difference in five-year overall survival between the Low and High BAR groups (p=0.079).
CONCLUSIONS: High BAR did not predict worse outcomes after RAPL for lung cancer in our study. Further studies are needed to better determine the prognostic ability of BAR in lower-risk populations.
摘要：
背景：血尿素氮与血清白蛋白之比（BAR）是一个新兴的感兴趣的预后参数。在接受肺叶切除术的肺癌患者中，尚未分析BAR作为预后因素的实用性。我们评估了高BAR预测机器人辅助肺叶切除术（RAPL）治疗肺癌后不良预后的能力。
方法：我们回顾性分析了2010年9月至2022年3月由一名外科医生接受RAPL的400例患者。根据低BAR（<6.25mg/g）和高BAR（≥6.25mg/g）对患者进行分层。患者人口统计学，肿瘤特征，合并症,手术并发症,结果，收集和生存率，并按高和低BAR组进行比较。感兴趣的主要结果是30天死亡率。
结果：受试者操作曲线（ROC）证实，6.25是基于低和高BAR估计死亡率的最佳阈值。低和高BAR组之间的手术并发症或结果没有差异。用曲线下面积（AUC）分析评估BAR预测30天死亡率的能力，这表明较高的BAR不能预测死亡率(AUC=0.655;95%CI,0.435-0.875;p=0.166)。同样，生存分析显示,低和高BAR组的5年总生存率无差异(p=0.079).
结论：在我们的研究中，高BAR并不能预测肺癌在RAPL治疗后预后较差。需要进一步的研究来更好地确定BAR在低风险人群中的预后能力。
方法：我们回顾性分析了2010年9月至2022年3月由一名外科医生接受RAPL的400例患者。根据低BAR（<6.25mg/g）和高BAR（≥6.25mg/g）对患者进行分层。患者人口统计学，肿瘤特征，合并症,手术并发症,结果，收集和生存率，并按高和低BAR组进行比较。感兴趣的主要结果是30天死亡率。
结果：受试者操作曲线（ROC）证实，6.25是基于低和高BAR估计死亡率的最佳阈值。低和高BAR组之间的手术并发症或结果没有差异。用曲线下面积（AUC）分析评估BAR预测30天死亡率的能力，这表明较高的BAR不能预测死亡率(AUC=0.655;95%CI,0.435-0.875;p=0.166)。同样，生存分析显示,低和高BAR组的5年总生存率无差异(p=0.079).
结论：在我们的研究中，高BAR并不能预测肺癌在RAPL治疗后预后较差。需要进一步的研究来更好地确定BAR在低风险人群中的预后能力。
